CHORD is a phase 1/2 in children with deafness due to variants of the otoferlin (OTOF) gene who are being treated with Regeneron's experimental adeno-associated virus (AAV) gene therapy DB-OTO in ...

Lilly is one of a clutch of companies looking to develop gene therapies for deafness caused by OTOF mutations, alongside the likes of Regeneron – which added a candidate called DB-OTO from its ...